List of Aragon Pharmaceuticals patents

Patents where

Current Assignee

Name

Aragon Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11224575 Anticancer compositions	Patent 11224575 was granted and assigned to Aragon Pharmaceuticals on January, 2022 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	11224575	January 18, 2022
‌ US Patent 9617602 Methods and compositions for determining resistance to androgen receptor therapy	Patent 9617602 was granted and assigned to Aragon Pharmaceuticals on April, 2017 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	9617602	April 11, 2017
‌ US Patent 11491149 Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer		Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	11491149	November 8, 2022
‌ US Patent 8455534 Estrogen receptor modulators and uses thereof	Patent 8455534 was granted and assigned to Aragon Pharmaceuticals on June, 2013 by the United States Patent and Trademark Office.		Aragon Pharmaceuticals	United States Patent and Trademark Office	8455534	June 4, 2013
‌ US Patent 10316015 Processes for the preparation of a diarylthiohydantoin compound	Patent 10316015 was granted and assigned to Aragon Pharmaceuticals on June, 2019 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	10316015	June 11, 2019
‌ US Patent 9340524 Androgen receptor modulator and uses thereof	Patent 9340524 was granted and assigned to Aragon Pharmaceuticals on May, 2016 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	9340524	May 17, 2016
‌ US Patent 11040953 Process for the preparation of a diarylthiohydantoin compound	Patent 11040953 was granted and assigned to Aragon Pharmaceuticals on June, 2021 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	11040953	June 22, 2021
‌ US Patent 10052314 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	Patent 10052314 was granted and assigned to Aragon Pharmaceuticals on August, 2018 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	10052314	August 21, 2018
‌ US Patent 10799489 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	Patent 10799489 was granted and assigned to Aragon Pharmaceuticals on October, 2020 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	10799489	October 13, 2020
‌ US Patent 10799488 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	Patent 10799488 was granted and assigned to Aragon Pharmaceuticals on October, 2020 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	10799488	October 13, 2020
‌ US Patent 10702508 Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer	Patent 10702508 was granted and assigned to Aragon Pharmaceuticals on July, 2020 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	10702508	July 7, 2020
‌ US Patent 10849888 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	Patent 10849888 was granted and assigned to Aragon Pharmaceuticals on December, 2020 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	10849888	December 1, 2020
‌ US Patent 10723714 Processes for the preparation of a diarylthiohydantoin compound		Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	10723714	July 28, 2020
‌ US Patent 11160796 Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer	Patent 11160796 was granted and assigned to Aragon Pharmaceuticals on November, 2021 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	11160796	November 2, 2021
‌ US Patent 9884054 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	Patent 9884054 was granted and assigned to Aragon Pharmaceuticals on February, 2018 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	9884054	February 6, 2018
‌ US Patent 10966930 Anticancer compositions	Patent 10966930 was granted and assigned to Aragon Pharmaceuticals on April, 2021 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	10966930	April 6, 2021
‌ US Patent 9481664 Androgen receptor modulators and uses thereof	Patent 9481664 was granted and assigned to Aragon Pharmaceuticals on November, 2016 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	9481664	November 1, 2016
‌ US Patent 9108944 Androgen receptor modulators and uses thereof	Patent 9108944 was granted and assigned to Aragon Pharmaceuticals on August, 2015 by the United States Patent and Trademark Office.		Aragon Pharmaceuticals	United States Patent and Trademark Office	9108944	August 18, 2015
‌ US Patent 8299112 Estrogen receptor modulators and uses thereof			Aragon Pharmaceuticals	United States Patent and Trademark Office	8299112	October 30, 2012
‌ US Patent 10023556 Androgen receptor modulators and uses thereof	Patent 10023556 was granted and assigned to Aragon Pharmaceuticals on July, 2018 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	10023556	July 17, 2018
‌ US Patent 11911511 Anticancer compositions	Patent 11911511 was granted and assigned to Aragon Pharmaceuticals on February, 2024 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	11911511	February 27, 2024
‌ US Patent 12018008 Crystalline forms of an androgen receptor modulator	Patent 12018008 was granted and assigned to Aragon Pharmaceuticals on June, 2024 by the United States Patent and Trademark Office.		Aragon Pharmaceuticals	United States Patent and Trademark Office	12018008	June 25, 2024
‌ US Patent 11903937 Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer	Patent 11903937 was granted and assigned to Aragon Pharmaceuticals on February, 2024 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	11903937	February 20, 2024
‌ US Patent 11963952 Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer	Patent 11963952 was granted and assigned to Aragon Pharmaceuticals on April, 2024 by the United States Patent and Trademark Office.	Aragon Pharmaceuticals	Aragon Pharmaceuticals	United States Patent and Trademark Office	11963952	April 23, 2024

24 results

0 selected

24 results

0 selected